| 000 | 01382 a2200409 4500 | ||
|---|---|---|---|
| 005 | 20250514003111.0 | ||
| 264 | 0 | _c20011204 | |
| 008 | 200112s 0 0 eng d | ||
| 022 | _a0176-3679 | ||
| 024 | 7 |
_a10.1055/s-2001-14282 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aFleischhacker, W W | |
| 245 | 0 | 0 |
_aA qualitative assessment of the neurological safety of antipsychotic drugs; an analysis of a risperidone database. _h[electronic resource] |
| 260 |
_bPharmacopsychiatry _cMay 2001 |
||
| 300 |
_a104-10 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntipsychotic Agents _xadverse effects |
| 650 | 0 | 4 |
_aBasal Ganglia Diseases _xchemically induced |
| 650 | 0 | 4 | _aClinical Trials as Topic |
| 650 | 0 | 4 | _aDatabases, Factual |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 | _aFactor Analysis, Statistical |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHaloperidol _xadverse effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aRisperidone _xadverse effects |
| 650 | 0 | 4 |
_aSchizophrenia _xcomplications |
| 700 | 1 | _aLemmens, P | |
| 700 | 1 | _avan Baelen, B | |
| 773 | 0 |
_tPharmacopsychiatry _gvol. 34 _gno. 3 _gp. 104-10 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1055/s-2001-14282 _zAvailable from publisher's website |
| 999 |
_c11363589 _d11363589 |
||